◆ TICKERBASE · GLOBAL STOCK FINANCIAL DATA LIBRARY
Nuvalent Inc (NUVL)
Storico di ricavi, utili e flussi di cassa dai bilanci ufficiali.
Healthcare · Wall Street (USA) · Ultimo aggiornamento: 2026-08-11
Nuvalent, Inc., a clinical-stage biopharmaceutical company, engages in the development of therapies for patients with cancer.
Dati chiave
- Capitalizzazione di mercato: $10 billion
- Ricavi (esercizio chiuso a 2025-12-31): $0M
- Utile netto: ($425M)
Vedi grafici interattivi e bilanci completi →
Conto economico annuale
| Conto economico | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|
| Entrate totali | $0M | $0M | $0M | $0M | — |
| Risultato Operativo (EBIT) | ($414M) | ($280M) | ($150M) | ($86M) | — |
| Reddito netto | ($425M) | ($261M) | ($126M) | ($82M) | — |
Fonte: bilanci pubblici della società (SEC). Verificare su SEC EDGAR prima di fare affidamento su qualsiasi cifra.
Stati patrimoniali, flussi di cassa, dati trimestrali e indici completi nel visualizzatore interattivo di NUVL. /companies/us/NUVL
Le informazioni di questo sito sono solo a scopo educativo e informativo; non costituiscono consulenza finanziaria. Non vengono pubblicati prezzi obiettivo né raccomandazioni.
About TickerBase · Data methodology & sources · Privacy · Terms
TickerBase is provided for educational and informational purposes only. It does not constitute financial, investment, tax, or legal advice, or a recommendation to buy, sell, or hold any security. No price targets are published; any per-share value shown in the valuation workbench is generated entirely from reader-supplied assumptions and is not the publisher's view of fair value. Past performance does not predict future results. Figures are approximate and drawn from public filings; one-time items are noted where identified. Do your own research and consult a licensed professional before making any investment decision. The author may or may not hold positions in the securities discussed.